A Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab in an Unsupervised Setting, Using Either an Auto-Injector or a Prefilled Syringe

Trial Profile

A Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab in an Unsupervised Setting, Using Either an Auto-Injector or a Prefilled Syringe

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Fasinumab (Primary)
  • Indications Pain
  • Focus Registrational; Therapeutic Use
  • Acronyms FACT DEVICE
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 13 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top